[go: up one dir, main page]

AR057242A2 - Composicion farmaceutica para administracion oral y uso de la misma en la fabricacion de un medicamento - Google Patents

Composicion farmaceutica para administracion oral y uso de la misma en la fabricacion de un medicamento

Info

Publication number
AR057242A2
AR057242A2 ARP060105534A ARP060105534A AR057242A2 AR 057242 A2 AR057242 A2 AR 057242A2 AR P060105534 A ARP060105534 A AR P060105534A AR P060105534 A ARP060105534 A AR P060105534A AR 057242 A2 AR057242 A2 AR 057242A2
Authority
AR
Argentina
Prior art keywords
manufacture
pharmaceutical composition
oral administration
compound
same
Prior art date
Application number
ARP060105534A
Other languages
English (en)
Inventor
Jean Francois Rossignol
Original Assignee
Romark Lab Lc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27420362&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR057242(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/852,447 external-priority patent/US5968961A/en
Priority claimed from US08/887,810 external-priority patent/US5856348A/en
Priority claimed from US08/887,809 external-priority patent/US5965590A/en
Application filed by Romark Lab Lc filed Critical Romark Lab Lc
Publication of AR057242A2 publication Critical patent/AR057242A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Composicion farmacéutica para administracion oral, caracterizada porque comprende como agente activo por lo menos un compuesto seleccionado del grupo integrado por: el compuesto de formula (1) y el compuesto de la formula (2) y un ácido farmacéuticamente aceptable para mejorar la estabilidad. También se revela el uso de estas composiciones en la fabricacion de un medicamento para tratar una infeccion provocada por un microorganismo seleccionado del grupo integrado por: Cryptosporidium parvum, isospora belli, Enterocytozoon bíeneusi, Encephalistozoon intestinalis, Mycobacterium tuberculosis, Mycobacterium avium intracellulare, Pneumocystis carinii y Toxoplasma gondii e infecciones parasitarias provocadas por trematodos.
ARP060105534A 1997-05-07 2006-12-14 Composicion farmaceutica para administracion oral y uso de la misma en la fabricacion de un medicamento AR057242A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/852,447 US5968961A (en) 1997-05-07 1997-05-07 Pharmaceutical compositions of tizoxanide and nitazoxanide
US08/887,810 US5856348A (en) 1994-09-08 1997-07-03 Method for treatment of trematodes with pharmaceutical compositions of tizoxanide and nitazoxanide
US08/887,809 US5965590A (en) 1994-09-08 1997-07-03 Method for treatment of opportunistic infections with pharmaceutical compositions of tizoxanide and nitazoxanide

Publications (1)

Publication Number Publication Date
AR057242A2 true AR057242A2 (es) 2007-11-21

Family

ID=27420362

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060105534A AR057242A2 (es) 1997-05-07 2006-12-14 Composicion farmaceutica para administracion oral y uso de la misma en la fabricacion de un medicamento

Country Status (34)

Country Link
EP (2) EP1222921B1 (es)
JP (1) JP3739802B2 (es)
KR (2) KR100576646B1 (es)
CN (2) CN100515420C (es)
AP (1) AP1103A (es)
AR (1) AR057242A2 (es)
AT (2) ATE281166T1 (es)
AU (1) AU740022B2 (es)
BG (2) BG109365A (es)
BR (1) BR9808722A (es)
CA (2) CA2288003C (es)
CZ (2) CZ298269B6 (es)
DE (2) DE69827417T2 (es)
DK (2) DK1222921T3 (es)
EA (2) EA002920B1 (es)
EE (1) EE04870B1 (es)
ES (2) ES2232687T3 (es)
GE (1) GEP20032970B (es)
HU (1) HU229641B1 (es)
IL (2) IL155799A (es)
IS (1) IS2087B (es)
LV (1) LV12492B (es)
ME (1) ME00530B (es)
NO (2) NO313983B1 (es)
NZ (2) NZ500149A (es)
OA (1) OA11169A (es)
PL (1) PL193275B1 (es)
PT (2) PT1222921E (es)
RO (1) RO120605B1 (es)
SI (1) SI20149B (es)
SK (2) SK283947B6 (es)
TR (1) TR199902733T2 (es)
UA (2) UA57079C2 (es)
WO (1) WO1998050035A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2467321A1 (en) 2004-05-14 2005-11-14 Paul J. Santerre Polymeric coupling agents and pharmaceutically-active polymers made therefrom
ES2422556T3 (es) 2006-01-09 2013-09-12 Romark Lab Lc Tratamiento de hepatitis vírica
JP5726766B2 (ja) * 2009-02-13 2015-06-03 ロマーク ラボラトリーズ エル．シー． ニタゾキサニドの制御放出医薬配合物
KR101760956B1 (ko) * 2009-05-12 2017-07-24 로마크 레버러토리즈, 엘.씨. 할로알킬 헤테로아릴 벤즈아미드 화합물
BRPI1014322A2 (pt) 2009-06-26 2015-08-25 Romark Lab Lc Método para tratar infecção, e para interromper ou evitar a produção de partículas virais infecciosas, combinação, e, composição farmacêutica.
EP2808019B1 (en) 2012-01-27 2019-09-25 Siegfried Rhein S.A. De C.V. Improved nitazoxanide composition and preparation method thereof
JP6633092B2 (ja) * 2014-11-11 2020-01-22 ロマーク ラボラトリーズ，リミティド カンパニー チゾキサニド、その類似体又は塩のプロドラッグを用いる組成物及び治療方法
KR20200121816A (ko) 2018-02-02 2020-10-26 리플 테라퓨틱스 코포레이션 스테로이드 이량체를 포함하는 유리 제제 및 이의 용도
WO2019241376A1 (en) 2018-06-14 2019-12-19 The Trustees Of Columbia University In The City Of New York Treatment of cognitive disorders using nitazoxanide (ntz), nitazoxanide (ntz) analogs, and metabolites thereof
WO2020154815A1 (en) 2019-02-01 2020-08-06 Ripple Therapeutics Corporation Crystalline forms of dexamethasone dimers and uses thereof
US20220347305A1 (en) 2019-08-07 2022-11-03 Ripple Therapeutics Corporation Controlled release drug dimers
CA3176134A1 (en) 2020-05-01 2021-11-04 Ripple Therapeutics Corporation Heterodimer compositions and methods for the treatment of ocular disorders
WO2022130406A1 (en) * 2020-12-15 2022-06-23 Cipla Limited Inhalation composition of nitazoxanide or its derivatives for use in coronavirus disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1437800A (en) * 1973-08-08 1976-06-03 Phavic Sprl Derivatives of 2-benzamido-5-nitro-thiazoles
US4315018A (en) * 1978-12-07 1982-02-09 Rossignol Jean F Specific parasiticidal use of 2-benzamido-5-nitro-thiazole derivatives
US5387598A (en) * 1994-04-13 1995-02-07 Rossignol; Jean-Francois Composition and galenic formulation suitable for combatting affections of the lower abdomen
US5578621A (en) * 1994-09-08 1996-11-26 Romark Lab Lc Benzamide derivatives

Also Published As

Publication number Publication date
IS2087B (is) 2006-03-15
SK283946B6 (sk) 2004-05-04
TR199902733T2 (xx) 2000-03-21
ATE281166T1 (de) 2004-11-15
AU740022B2 (en) 2001-10-25
PT1222921E (pt) 2005-02-28
ME00530B (me) 2011-10-10
IS5223A (is) 1999-10-19
IL132516A0 (en) 2001-03-19
IL155799A (en) 2004-08-31
RO120605B1 (ro) 2006-05-30
HUP0003330A3 (en) 2002-10-28
SI20149A (sl) 2000-08-31
DK1005342T3 (da) 2003-03-24
EE9900578A (et) 2000-08-15
LV12492B (en) 2001-01-20
CA2288003A1 (en) 1998-11-12
DE69809928T2 (de) 2003-04-24
SI20149B (en) 2001-08-31
AP9901675A0 (en) 1999-12-31
CA2418634C (en) 2004-10-26
UA57079C2 (uk) 2003-06-16
CN100515420C (zh) 2009-07-22
NO20021832L (no) 2000-01-04
SK151199A3 (en) 2000-07-11
CA2418634A1 (en) 1998-11-12
CN1552322A (zh) 2004-12-08
JP2001503067A (ja) 2001-03-06
NO995406D0 (no) 1999-11-04
DE69809928D1 (de) 2003-01-16
EP1005342B1 (en) 2002-12-04
PL336805A1 (en) 2000-07-17
SK283947B6 (sk) 2004-05-04
JP3739802B2 (ja) 2006-01-25
PT1005342E (pt) 2003-02-28
BR9808722A (pt) 2000-07-11
IL132516A (en) 2003-12-10
EA199901012A1 (ru) 2000-08-28
BG64973B1 (bg) 2006-11-30
DE69827417D1 (de) 2004-12-09
OA11169A (en) 2003-04-25
CZ298269B6 (cs) 2007-08-08
CN1255060A (zh) 2000-05-31
HU229641B1 (en) 2014-03-28
EE04870B1 (et) 2007-08-15
EA002908B1 (ru) 2002-10-31
AP1103A (en) 2002-09-04
PL193275B1 (pl) 2007-01-31
NO313983B1 (no) 2003-01-13
NO335781B1 (no) 2015-02-16
EP1005342A4 (en) 2001-02-07
EP1005342A1 (en) 2000-06-07
BG103958A (en) 2000-07-31
DE69827417T2 (de) 2005-10-27
CA2288003C (en) 2003-10-21
GEP20032970B (en) 2003-05-27
KR20040004544A (ko) 2004-01-13
AU7289598A (en) 1998-11-27
NO20021832D0 (no) 2002-04-18
CZ391199A3 (cs) 2000-07-12
KR100576646B1 (ko) 2006-05-08
ES2150404T3 (es) 2003-07-01
UA74388C2 (uk) 2005-12-15
HUP0003330A2 (hu) 2001-05-28
CN1158074C (zh) 2004-07-21
EA002920B1 (ru) 2002-10-31
NO995406L (no) 2000-01-04
EP1222921B1 (en) 2004-11-03
BG109365A (en) 2006-08-31
WO1998050035A1 (en) 1998-11-12
ES2232687T3 (es) 2005-06-01
NZ500149A (en) 2001-11-30
LV12492A (en) 2000-06-20
NZ513881A (en) 2002-10-25
EP1222921A1 (en) 2002-07-17
ES2150404T1 (es) 2000-12-01
HK1025907A1 (en) 2000-12-01
IL155799A0 (en) 2003-12-23
KR20010020322A (ko) 2001-03-15
EA200100956A1 (ru) 2002-02-28
KR100426657B1 (ko) 2004-04-13
ATE228839T1 (de) 2002-12-15
CZ298270B6 (cs) 2007-08-08
DK1222921T3 (da) 2005-03-07

Similar Documents

Publication Publication Date Title
AR057242A2 (es) Composicion farmaceutica para administracion oral y uso de la misma en la fabricacion de un medicamento
BR0108435A (pt) Formulação e uso de entecavir de baixa dose
EP0379147A3 (en) Extrudable elastic gel for use as carrier for therapeutic agent
CO4950538A1 (es) Composiciones farmaceuticas de la tizoxadina y la nitazoxadina
BR9810320A (pt) Composição farmacêutica sólida, contendo derivados de benzofurano
YU49698A (sh) Smeše koje sadrže tetrahidrolipstatin
KR910009243A (ko) 치근막 질환 치료용 서방성 조성물
DE50005515D1 (de) Mechanisch stabile pharmazeutische darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive substanzen
HUP0100801A2 (hu) Metformin és fibrát kombinációját tartalmazó gyógyászati készítmények és ezek alkalmazása kórosan magas vércukorszint csökkentését célzó gyógyszerek előállítására
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
BRPI9708706C8 (pt) composição farmacêutica para administração intravenosa a um paciente
ES2159591T3 (es) Composicion de liberacion controlada.
CA2385890A1 (en) Controlled release compositions comprising nimesulide
WO2004108162A3 (en) Controlled release pharmaceutical composition
TR200101088T2 (tr) Sürekli salınımlı farmasötik kompozisyon ve farmasötik olarak aktif ajanın salınma metodu
KR960000247A (ko) 사이클로스포린a 함유 조성물 및 그의 제조방법
KR910009241A (ko) 치근막 질환 치료용 서방성 조성물
EP1383540A4 (en) METHODS AND PHARMACEUTICAL COMPOSITIONS FOR Wounds Healing
AR002701A1 (es) Composición transdermica, uso y dispositivo estabilizado.
KR910018348A (ko) 술포닐아미노치환 비시클로환계 히드록삼산 유도체
SE0302924D0 (sv) Pharmaceutical composition having a cationic excipient
BR0014440A (pt) Formulações de liberação controlada oral
HRP20020258B1 (hr) Farmaceutska kombinacija etinilestradiola i drospirenona za upotrebu kao kontracepcijskog sredstva
ES2113136T3 (es) Composiciones farmaceuticas de gemfibrozil y procedimiento para su preparacion.
AR030551A1 (es) Uso de nefiracetam para la fabricacion de un medicamento para eltratamiento de la neurodegeneracion y composicion farmaceutica resultante

Legal Events

Date Code Title Description
FC Refusal